The Hedgehog Pathway Inhibitors market is predicted to grow at a CAGR of 10.3%, with forecasts for 2030 eclipsing USD 961.7 million. The market is driven by the increasing prevalence of cancer, hereditary factors, new product launches, increasing demand for painless or minimally invasive treatment, and increased resistance to existing therapies. Hedgehog signaling pathway is expected to be one of the vital therapies for cancer treatment in the forecast period. Hedgehog pathway inhibitors prevent the Hedgehog-ligand (signal). The rising prevalence of cancer is boosting the market for Hedgehog pathway inhibitors. Approximately 1,735,350 new cancer cases were registered for 2018 in the US. Nearly 9,500 people in the US are a target of skin cancer or Basal Cell Carcinoma. Estimation says that non-melanoma carcinoma, including basal cell carcinoma and squamous cell carcinoma, affects more than 3 million globally per year. Increased exposure to chemicals and the polluted environment is resulting in DNA defect, which can be one of the causes of chronic diseases like Gorlin Syndrome. Statins, in combination with the Hedgehog pathway inhibitor, synergize the action of inhibitors for the treatment of Medulloblastoma.
Hedgehog pathway inhibitors are more preferred than the available alternatives for the treatment of cancer due to the increased demand for painless treatment. People often discontinue the medication or avoid the treatment because of the anxiety and stress of carrying out a painful procedure and a more extended period of hospital stay, wherein Hedgehog pathway inhibitors are either taken orally or applied topically, which is convenient and painless. This might drive the market growth. However, side effects associated with the drug might hamper market growth.
Request a Sample@ https://qyresearchmedical.com/sample/118988
Salient Features of the Hedgehog Pathway Inhibitors Market
- Strongest driving forces are the global rise in the prevalence of chronic target diseases such as cancer, product launches in the market, and increasing demand of minimally invasive to painless treatment.
- Various market players have engaged in producing user-friendly technique for cancer treatment. For instance, Pellepharm has introduced Saridegib (Patidegib) a hedgehog pathway inhibitor. It is used as topical treatment measure, for patients with Gorlin Syndrome and Basal Cell Carcinomas (BCCs).
- Various organizations such as Austrian Science Fund (FWF), different startup grants from universities such as Fudan University, government agencies such as The National Cancer Institute, National Natural Science Foundation of China, and other governmental bodies provide funds for companies to motivate innovation and anticipation in key players in eradication of respective infectious diseases.
- Marketing strategies such as acquisition, divestitures etc. are also expected to propel the market growth. For instance, Sun Pharmaceutical Industries Ltd. Acquired Novartis pipeline product Odomzo (Sonidegib).
Companies Considered
Pfizer Inc., F. Hoffmann-La Roche AG, Sun Pharmaceutical Industries Limited, Infinity Pharmaceuticals, Max Biopharma Inc, PellePharm Inc., Takeda Pharmaceutical Company Ltd, Mayne Pharma Group Limited, Bristol-Myers Squibb Company are dominating players in the market and have been extensively studied in this report.
Market-o-Nomics
- The cost of manufacturing Hedgehog pathway inhibitors is higher and adverse effects associated with the drugs may affect the market growth
- The basal cell carcinoma indication segment held a larger part of the market, with a CAGR at 11.2% as it is the most prevalent disease and encountering higher estimation of newer cases in dominant regional market
- On the basis of route of administration, oral passage for the delivery of inhibitors holds the largest market share. Oral drugs require no special skills and can easily carry around. These factors are expected to propel the oral Hedgehog pathway inhibitors market.
- On the basis of pathway type, smoothened dependent non-canonical is expected to be the fastest-growing segment holding larger market share than the other types of the Hedgehog pathway.
- Due to increasing levels of disposable income and increasing awareness towards availability of new strategical treatments, the market is expected to experience substantial growth.
- The Asia-Pacific market is estimated to be the fastest growing regional segment at a CAGR of 11.4% during the forecast period, owing to growing target diseases and increasing FDI and R&D investments in emerging countries of Asia Pacific such as China and India, improved regulatory framework.
- North America is expected to be the chief revenue generator of the market in the forecasted period, as the presence of major companies contributing higher global revenue in pharmaceutical sector through its new molecule (clinical) pipeline belongs to the North American region.
Key Coverage of the Report
- Region/country wide statistics with respect to year, regional prevalence
- Regional Competitors clinical pipeline analysis
- Estimation of market size
- Types of Products
- Upcoming products analyzed
- Alternatives analyzed
- Types of use analyzed
- Status of ongoing developments
- Analysis of regulatory framework/regulatory bodies
- Demand and supply gap analysis
- Competitor pricing strategy
- Market share analysis
- Strategic recommendations for new entrants/existing members/ key business segments
- Market trends
- Drivers, constraints, opportunities, threats, challenges, investment opportunities
- Competitive landscaping
- Company profiling with strategies, financials and recent developments
Segments Covered
This report predicts revenue growth and CAGR at a global, regional & country level, and analyses the markets by studying the drivers, constraints, opportunities, threats, challenges, investment opportunities, products, uses, trends, market shares in each of the sub-segments from 2019 to 2030. For the purpose of this study, Reports and Data has segmented the global Hedgehog Pathway Inhibitors market report based on product type, pathway type, application, route of administration, patient use and region:
Product Type Outlook (Revenue, USD Million; 2019-2030)
- Glasdegib
- Vismodegib
- Sonidegib
- Itraconazole
- Oxysterol
- Saridegib
Pathway Type Outlook (Revenue, USD Million; 2019-2030)
- Canonical Hedgehog Signaling
- Non-Canonical Hedgehog Signaling
- Smoothened dependent Non-Canonical
- Smoothened independent Non-Canonical
Application Outlook (Revenue, USD Million; 2019-2030)
- Basal Cell Carcinoma
- Acute Myeloid Leukemia
- Medulloblastoma
- Gorlin Syndrome
- Others
Route of Administration Outlook (Revenue, USD Million; 2019-2030)
- Oral
- Topical
Patient Use Outlook (Revenue, USD Million; 2019-2030)
- Adult
- Children
Regional Outlook (Revenue, USD Million; 2019-2030)
- North America
- U.S.
- Canada
- Europe
- Germany
- France
- UK
- Spain
- Italy
- Rest of the Europe
- Asia Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Middle East & Africa
- Latin America
- Brazil
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/118988/1500
You can place an order or ask any questions, please feel free to contact [email protected] | +1 9197 992 333
Blog: https://www.novaoneadvisor.com/
Blog: https://www.visionresearchreports.com/
About Us
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us:
URL – http://www.qyresearchmedical.com/
https://www.linkedin.com/company/qyresearch-medical/
https://www.facebook.com/QYResearch-Medical-108186514228917/